Concord Drugs Limited

CONCORD6

INE858L01010

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:52 2024-05-28 am EDT			5-day change	1st Jan Change
39.14 ^INR	+3.16%		-0.53%	-34.46%

Mar. 19	Concord Drugs Limited Announces Appointment of Namratha Nagla as Company Secretary/Compliance Officer	CI
Feb. 13	Concord Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Concord Drugs Limited Appoints RakshitSethiya as Company Secretary and Compliance Officer

November 04, 2022 at 06:33 am EDT

Concord Drugs Limited announced that the company has received consent letter from Mr. RakshitSethiya, to act as the company secretary and compliance officer of the company, effective November 4, 2022. He is an Associate member of the ICSI and a B.com graduate and has rich experience of 1 year in Secretarial works.

Latest news about Concord Drugs Limited

Concord Drugs Limited Announces Appointment of Namratha Nagla as Company Secretary/Compliance Officer	Mar. 19	CI
Concord Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 13	CI
Concord Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 14	CI
Concord Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
Concord Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
Concord Drugs Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-30	CI
Concord Drugs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-30	CI
Concord Drugs Eyes INR 207 Million Rights Issue	23-04-14	MT
Concord Drugs Limited Announces Resignation of AnkurBisht, Company Secretary and Compliance Officer	23-04-08	CI
Concord Drugs Limited acquired 100% stake in Proton Remedies Private Limited for INR 14.2 million.	23-03-22	CI
Concord Drugs Limited Appoints Mr. Ankur Bisht as Company Secretary and Compliance Officer, Effective on February 16, 2023	23-02-14	CI
Concord Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Concord Drugs Limited Announces Resignation of Rakshit Sethiya as Company Secretary and Compliance Officer	22-11-11	CI
Concord Drugs Limited announced that it has received INR 10.364063 million in funding	22-11-06	CI
Concord Drugs Limited Appoints RakshitSethiya as Company Secretary and Compliance Officer	22-11-04	CI
Concord Drugs Limited announced that it expects to receive INR 10.364063 million in funding	22-09-06	CI
Concord Drugs Limited agreed to acquire 100% stake in Proton Remedies Private Limited.	22-09-06	CI
Concord Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-13	CI
Concord Drugs Limited Announces Director Changes	22-06-02	CI
Concord Drugs Limited Announces Resignation of Jyoti Goyal as Company Secretary and Compliance Officer	22-05-06	CI
Concord Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-14	CI
Concord Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-10-18	CI
Concord Drugs Limited Approves Appointment of S. Koni Reddy as Whole Time Director	21-09-08	CI
Concord Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	21-08-13	CI
Concord Drugs Limited Approves Resignation of T. Narsihma Reddy as Managing Director	21-08-13	CI

Chart Concord Drugs Limited

Duration

Period

More charts

Company Profile

Concord Drugs Limited is an India-based pharmaceutical company. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved. The Company offers finished pharmaceutical formulations, such as injectables (small volume parenteral, dry powders), tissue bio-adhesive, tablets, capsules, liquid orals (syrup and suspension) and dry syrups (powder). The Company also provides ready-to-fill pellets and multiple unit pellet system (MUPS). Its injectables include Amikacin Injection, Aceclofenac Injection, Artemether Injection, Adenosine Injection, and others. Iso Amyl 2-Cyano Acrylate is a tissue bio-adhesive. Its pellets are categorized as gastrointestinal drug pellets, cardiovascular drug pellets, respiratory drug pellets, anti-obesity drug pellets, anti-depressant drug pellets, central nervous system drug pellets, urological drug pellets, anti-microbial, anti-infective and adjuvant drugs pellets, taste mask drug pellets/powder, and others.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CONCORD DRUGS LIMITED	-34.46%	4.56M
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+31.99%	594B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+14.87%	243B
NOVARTIS AG	+7.74%	205B
ROCHE HOLDING AG	-6.05%	203B
AMGEN INC.	+6.19%	164B